RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 101 filers reported holding RHYTHM PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $8,307,505 | -0.9% | 202,326 | +4.5% | 0.00% | 0.0% |
Q1 2024 | $8,385,352 | +30.5% | 193,523 | +38.4% | 0.00% | 0.0% |
Q4 2023 | $6,426,698 | +104.0% | 139,802 | +1.7% | 0.00% | 0.0% |
Q3 2023 | $3,150,880 | +36.3% | 137,443 | -2.0% | 0.00% | – |
Q2 2023 | $2,312,245 | +16.1% | 140,221 | +25.6% | 0.00% | – |
Q1 2023 | $1,991,532 | -36.0% | 111,633 | +4.4% | 0.00% | -100.0% |
Q4 2022 | $3,113,394 | -17.1% | 106,916 | -30.2% | 0.00% | 0.0% |
Q3 2022 | $3,754,000 | +957.5% | 153,213 | +79.1% | 0.00% | – |
Q2 2022 | $355,000 | -64.1% | 85,565 | -0.3% | 0.00% | – |
Q1 2022 | $989,000 | -86.7% | 85,811 | -88.5% | 0.00% | -100.0% |
Q4 2021 | $7,444,000 | -32.6% | 745,883 | -11.8% | 0.00% | -50.0% |
Q3 2021 | $11,048,000 | -56.5% | 845,952 | -34.7% | 0.00% | -50.0% |
Q2 2021 | $25,377,000 | +17.5% | 1,296,081 | +27.7% | 0.00% | 0.0% |
Q1 2021 | $21,595,000 | -65.4% | 1,015,302 | -51.7% | 0.00% | -66.7% |
Q4 2020 | $62,469,000 | +21.4% | 2,101,227 | -11.5% | 0.01% | +9.1% |
Q3 2020 | $51,452,000 | -11.2% | 2,374,348 | -8.6% | 0.01% | -15.4% |
Q2 2020 | $57,913,000 | +42.6% | 2,596,923 | -2.7% | 0.01% | +18.2% |
Q1 2020 | $40,611,000 | -46.7% | 2,668,228 | -19.6% | 0.01% | -31.2% |
Q4 2019 | $76,244,000 | +216.9% | 3,320,751 | +198.0% | 0.02% | +220.0% |
Q3 2019 | $24,059,000 | +101.5% | 1,114,347 | +105.4% | 0.01% | +66.7% |
Q2 2019 | $11,938,000 | -24.9% | 542,630 | -6.4% | 0.00% | -25.0% |
Q1 2019 | $15,892,000 | -1.9% | 579,779 | -3.8% | 0.00% | 0.0% |
Q4 2018 | $16,196,000 | +50.8% | 602,514 | +63.6% | 0.00% | +100.0% |
Q3 2018 | $10,743,000 | -4.6% | 368,290 | +2.3% | 0.00% | -33.3% |
Q2 2018 | $11,257,000 | +3.7% | 360,075 | -34.0% | 0.00% | +50.0% |
Q1 2018 | $10,851,000 | -31.5% | 545,256 | 0.0% | 0.00% | -50.0% |
Q4 2017 | $15,845,000 | – | 545,256 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Opaleye Management Inc. | 735,000 | $13,112,400 | 3.93% |
NEA Management Company, LLC | 2,909,956 | $51,913,615 | 3.59% |
Frazier Life Sciences Management, L.P. | 2,164,739 | $38,618,944 | 2.80% |
RA Capital Management | 5,516,067 | $98,406,635 | 2.23% |
Samsara BioCapital, LLC | 345,293 | $6,160,027 | 1.27% |
Rock Springs Capital Management LP | 1,597,123 | $28,492,674 | 0.68% |
Baker Brothers Advisors | 6,498,267 | $115,929,083 | 0.63% |
HighVista Strategies LLC | 35,478 | $632,928 | 0.52% |
Nan Fung Group Holdings Ltd | 32,520 | $580,157 | 0.40% |
GREAT POINT PARTNERS LLC | 97,544 | $1,740,185 | 0.34% |